Bharat Biotech has emphasised the need for more comprehensive ... out for several hundred thousand subjects. The safety of Covaxin was also evaluated by the Ministry of Health, Govt of India.

Bharat Biotech's COVID-19 vaccine Covaxin was on Tuesday recommended by an expert panel for phase II/III clinical trial on those aged between two to 18 years, official sources said. The trial ...

Covaxin was developed by Bharat Biotech in partnership with the Medical Research Council of India, the government research body. The vaccine is made from a killed coronavirus to elicit an immune ...

But only 1.2 million, or about 11%, of them have taken COVAXIN, the locally developed vaccine from Bharat Biotech, while the remaining 9.4 million have used the vaccine licensed from AstraZeneca ...

COVAXIN, India's indigenous COVID-19 vaccine by Bharat Biotech is developed in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV). Makers of ...

Bharat Biotech is also looking at nasal vaccine as a booster dose as its scaling up capacity is very easy when compared with Covaxin, he added. About the importance of nasal vaccine, he said the ...

His work led to the development of India’s first indigenous Covid-19 vaccine, Covaxin. Bharat Biotech, established in 1996, has delivered over nine billion vaccine doses worldwide. This year's ...

During the Covid-19 pandemic, apart from the injectable two-dose Covaxin, Bharat Biotech also developed a novel intranasal vaccine called iNCOVACC. INSA, established in 1935, plays a crucial role ...

A single dose of Bharat Biotech’s intranasal vaccine iNCOVACC ... both as a booster shot for those fully vaccinated with Covaxin or Covishield, as well as a primary vaccine for a full two ...